ABVC BioPharma Receives $566,000 in Cumulative Payments Under Vitargus Licensing Agreement

ABVC BioPharma has received a $70,000 licensing payment from partner ForSeeCon Eye Corporation, bringing cumulative payments under their global licensing agreement for Vitargus to $566,000. The agreement represents a potential total value of up to $93.5 million, including $3.5 million in cash licensing payments, up to $30 million in equity consideration, and up to $60 million in future royalties.

The company plans to allocate the new licensing income to its Good Manufacturing Practice pharmaceutical facility in Hsinchu, Taiwan, specifically to prepare for GMP-compliant production of Vitargus. This facility represents a critical milestone in moving the biodegradable vitreous substitute from development into scalable, regulatory-compliant manufacturing necessary for future commercialization.

Since the start of fiscal 2025, ABVC has received a total of $1,345,950 in licensing revenues across all current partnerships. These revenues come with minimal incremental costs as development expenses were largely incurred in prior years, enabling the company to capture high-margin revenues that directly enhance its financial position while supporting strategic reinvestments.

Vitargus is positioned to address a significant market opportunity, with independent market research estimating the global vitreous substitute market at $2.5 billion in 2024, projected to grow to $4.1 billion by 2033 according to market research data. The novel vitreous substitute is designed to improve retinal surgery outcomes by eliminating the need for face-down positioning during recovery.

Dr. Uttam Patil, ABVC's Chief Executive Officer, stated that the company has secured $1.35 million in licensing revenues across multiple partnerships in 2025 alone. These high-margin revenues enable direct reinvestment into the Hsinchu GMP facility, representing a critical step toward moving Vitargus to commercialization and delivering long-term shareholder value.

ABVC's licensing framework with multiple partners, including AiBtl, ForSeeCon, and OncoX, positions the company to capture both near-term liquidity and long-term growth opportunities in central nervous system disorders, oncology, and ophthalmology. The company anticipates receiving more than $12 million in future receivables through these partnerships.

The development of GMP-compliant manufacturing capabilities for Vitargus represents a significant advancement in ophthalmic treatment options. As a clinical-stage biopharmaceutical company, ABVC maintains an active pipeline of six drugs and one medical device under development, utilizing in-licensed technology from research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center.